Obicetrapib

Phase 3Small molecule

NNewAmsterdam Pharma

Obicetrapib is one of 84 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Metabolic SyndromePhase 3

Active, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 3

Injectafer

AAmerican Regent, Inc.

Phase 3

1 4

Retatrutide

Eli Lilly

Phase 3

1 5

TAK-875

Takeda

Phase 3

1 6

Obicetrapib

NNewAmsterdam Pharma

Phase 3

1 7

Repatha

Amgen

Preclinical

5 8

Farxiga

AstraZeneca

Preclinical

1 9

Mounjaro

Eli Lilly

Preclinical

1 10

Praluent

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cardiovascular Disease

NCT05202509

Phase 2Recruiting

ART

NCT06982508

Q1 2027

Phase 3Recruiting

Imaging

NCT06305559

Q2 2028

Phase 3Recruiting

Metabolic Syndrome

NCT07219602

Clinical

Trials by Indication[1]

Randomized3 trials

Randomized Study of Obicetrapib in Combination With Ezetimibe

Completed·NNewAmsterdam Pharma·Phase 2·NCT04770389·112 enrolled

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Completed·NNewAmsterdam Pharma·Phase 3·NCT05142722·2,530 enrolled

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Completed·NNewAmsterdam Pharma·Phase 2·NCT04753606·120 enrolled

Imaging1 trial

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Recruiting·NNewAmsterdam Pharma·Phase 3·NCT06305559·300 enrolled

MPA1 trial

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Recruiting·NNewAmsterdam Pharma·Phase 2·NCT06496243·69 enrolled

Metabolism1 trial

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Active, not recruiting·NNewAmsterdam Pharma·Phase 1·NCT05972278·22 enrolled

Oral1 trial

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Completed·NNewAmsterdam Pharma·Phase 1·NCT06250205·30 enrolled

10 more indications

Lip1 trial

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Completed·NNewAmsterdam Pharma·Phase 3·NCT05425745·354 enrolled

Atorvastatin1 trial

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

Completed·NNewAmsterdam Pharma·Phase 1·NCT06081166·74 enrolled

Metabolic Syndrome1 trial

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Recruiting·NNewAmsterdam Pharma·Phase 3·NCT07219602·300 enrolled

ART1 trial

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Recruiting·NNewAmsterdam Pharma·Phase 2·NCT06982508·100 enrolled

Drug Interactions1 trial

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

Completed·NNewAmsterdam Pharma·Phase 1·NCT06547359·94 enrolled

Statin1 trial

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Completed·NNewAmsterdam Pharma·Phase 2·NCT05421078·102 enrolled

Cardiovascular Disease1 trial

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting·NNewAmsterdam Pharma·Phase 3·NCT05202509·9,541 enrolled

Moderate Hepatic Impairment1 trial

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Completed·NNewAmsterdam Pharma·Phase 1·NCT06048302·18 enrolled

Early Alzheimer's Disease1 trial

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Completed·NNewAmsterdam Pharma·Phase 2·NCT05161715·13 enrolled

Unspecified1 trial

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Completed·NNewAmsterdam Pharma·Phase 2·NCT05266586·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Obicetrapib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Obicetrapib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Obicetrapib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NewAmsterdam Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNewAmsterdam Pharma

Obicetrapib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2028

Trials by Indication[1]

Randomized3 trials

Imaging1 trial

MPA1 trial

Metabolism1 trial

Oral1 trial

Lip1 trial

Atorvastatin1 trial

Metabolic Syndrome1 trial

ART1 trial

Drug Interactions1 trial

Statin1 trial

Cardiovascular Disease1 trial

Moderate Hepatic Impairment1 trial

Early Alzheimer's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News